EuroBiotech—More articles of note

(NS Newsflash/CC BY 2.0)

> Innate Pharma agreed to trial anti-C5aR monoclonal antibody IPH5401 in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi. The phase 1/2 trial will assess the effect of the combination in patients with certain types of solid tumors. Statement

> BerGenBio posted data from phase 2 trials that are administering its AXL inhibitor in combination with Merck’s Keytruda. Release 

> Helsinn Healthcare joined with Scientific Centre of Monaco to develop pharmacological inhibitors in kidney cancer. Release 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Sanofi filed for European approval of a sleeping sickness treatment. The French pharma worked on the therapy with the Drugs for Neglected Disease Initiative. Statement

> Affimed shared data from a trial that tested NK cell engager candidate AFM13 in combination with Keytruda. Statement

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.